 |
|
Researchers coat titanium with polymer to improve integration of joint replacements
July 02, 2008Research at the Georgia Institute of Technology shows that coating a titanium implant with a new biologically inspired material enhances tissue healing, improves bone growth around the implant and strengthens the attachment and integration of the implant to the bone.
"We designed a coating that specifically communicates with cells and we're telling the cells to grow bone around the implant," said Andrés García, professor and Woodruff Faculty Fellow in Georgia Tech's Woodruff School of Mechanical Engineering and the Petit Institute for Bioengineering and Bioscience.
Details of the new coating appear in the July issue of the journal Biomaterials. The research was supported by the National Institutes of Health, the Arthritis Foundation and the Georgia Tech/Emory National Science Foundation Engineering Research Center on the Engineering of Living Tissues.
Total knee and hip replacements typically last about 15 years until the components wear down or loosen. For many younger patients, this means a second surgery to replace the first artificial joint. With approximately 40 percent of the 712,000 total hip and knee replacements in the United States in 2004 performed on younger patients 45-64 years old, improving the lifetime of the titanium joints and creating a better connection with the bone becomes extremely important.
Current clinical practice includes roughening the surface of the titanium implant or coating it with a flaky, hard-to-apply ceramic that bonds directly to bone.
In collaboration with Georgia Tech School of Chemistry and Biochemistry professor David Collard, graduate students Tim Petrie and Jenny Raynor, and research technician Kellie Burns, García coated the titanium with a thin, dense polymer.
"Our coating consists of a high density of polymer strands, akin to the bristles on a toothbrush, that we can then modify to present our bio-inspired, bioactive protein," explained García.
In this case, the polymer presented controlled amounts of an engineered protein that mimics fibronectin, a protein in the body that acts as a binding site for cell surface receptors called integrins.
It is important to control the integrins binding to the titanium implant because integrins provide signals that direct bone formation. Therefore, controlling integrin binding to the titanium will result in targeted signals that enhance bone formation around the implant.
To bind integrins to titanium, researchers previously coated titanium with a small biological signal containing the sequence arginine-glycine-aspartic acid (RGD) that binds to integrins. However, this region alone binds many different integrin receptors and with much less affinity than the full fibronectin protein.
"It has been common to mimic only very small sections of fibronectin, but when you take a small section and ignore the rest of the molecule you lose specificity and activity, and therefore signaling is impaired," said García.
For that reason, García engineered a much longer region of the same type of fibronectin that included the RGD peptide sequence as well as new sections also known to have sites that participate in integrin binding.
To evaluate the in vivo performance of the coated titanium in bone healing, chemists Raynor and Collard coated the surfaces of tiny clinical-grade titanium cylinders with the polymer brushes. Then engineers Petrie and García modified them with peptide sequences.
Two-millimeter circular defects were drilled into a rat's tibia bone and the cylinders were pressed into the holes. They tested three types of coatings: uncoated titanium, titanium coated with the RGD peptide and titanium coated with different densities of the engineered fibronectin fragment.
To investigate the function of these novel surfaces in promoting bone growth, the researchers quantified osseointegration, or the growth of bone around the implant and strength of the attachment of the implant to the bone.
Analysis of the bone-implant interface four weeks later revealed extensive and contiguous bone matrix and a 70 percent enhancement in the amount of contact between the implant and bone with the titanium implants coated with the engineered fibronectin fragment over the uncoated or RGD-coated titanium.
García and Petrie tested the fixation of the implants by measuring the amount of force required to pull the implants out of the bone. The study showed significantly higher mechanical fixation of the implants coated with the engineered fibronectin fragment over the implants with the other coating and uncoated titanium.
In addition to total joint replacements, García is studying how to fill large gaps between bones, which sometimes occur after a traumatic injury or tumor removal.
"We are developing a strategy to present peptides that encourage the surrounding bone to grow in and fill in around the gap," said García.
By improving communication with the body's cells, García can control the integration and healing response of the body to any implanted device. Currently, most become encapsulated by a collagen sheath, which affects the performance and long-term viability of the device. García aims to use these biomaterials to help integrate devices implanted in the body.
Georgia Institute of Technology Research News
Total knee and hip replacements typically last about 15 years until the components wear down or loosen. For many younger patients, this means a second surgery to replace the first artificial joint. With approximately 40 percent of the 712,000 total hip and knee replacements in the United States in 2004 performed on younger patients 45-64 years old, improving the lifetime of the titanium joints and creating a better connection with the bone becomes extremely important.
Current clinical practice includes roughening the surface of the titanium implant or coating it with a flaky, hard-to-apply ceramic that bonds directly to bone.
In collaboration with Georgia Tech School of Chemistry and Biochemistry professor David Collard, graduate students Tim Petrie and Jenny Raynor, and research technician Kellie Burns, García coated the titanium with a thin, dense polymer.
"Our coating consists of a high density of polymer strands, akin to the bristles on a toothbrush, that we can then modify to present our bio-inspired, bioactive protein," explained García.
In this case, the polymer presented controlled amounts of an engineered protein that mimics fibronectin, a protein in the body that acts as a binding site for cell surface receptors called integrins.
It is important to control the integrins binding to the titanium implant because integrins provide signals that direct bone formation. Therefore, controlling integrin binding to the titanium will result in targeted signals that enhance bone formation around the implant.
To bind integrins to titanium, researchers previously coated titanium with a small biological signal containing the sequence arginine-glycine-aspartic acid (RGD) that binds to integrins. However, this region alone binds many different integrin receptors and with much less affinity than the full fibronectin protein.
"It has been common to mimic only very small sections of fibronectin, but when you take a small section and ignore the rest of the molecule you lose specificity and activity, and therefore signaling is impaired," said García.
For that reason, García engineered a much longer region of the same type of fibronectin that included the RGD peptide sequence as well as new sections also known to have sites that participate in integrin binding.
To evaluate the in vivo performance of the coated titanium in bone healing, chemists Raynor and Collard coated the surfaces of tiny clinical-grade titanium cylinders with the polymer brushes. Then engineers Petrie and García modified them with peptide sequences.
Two-millimeter circular defects were drilled into a rat's tibia bone and the cylinders were pressed into the holes. They tested three types of coatings: uncoated titanium, titanium coated with the RGD peptide and titanium coated with different densities of the engineered fibronectin fragment.
To investigate the function of these novel surfaces in promoting bone growth, the researchers quantified osseointegration, or the growth of bone around the implant and strength of the attachment of the implant to the bone.
Analysis of the bone-implant interface four weeks later revealed extensive and contiguous bone matrix and a 70 percent enhancement in the amount of contact between the implant and bone with the titanium implants coated with the engineered fibronectin fragment over the uncoated or RGD-coated titanium.
García and Petrie tested the fixation of the implants by measuring the amount of force required to pull the implants out of the bone. The study showed significantly higher mechanical fixation of the implants coated with the engineered fibronectin fragment over the implants with the other coating and uncoated titanium.
In addition to total joint replacements, García is studying how to fill large gaps between bones, which sometimes occur after a traumatic injury or tumor removal.
"We are developing a strategy to present peptides that encourage the surrounding bone to grow in and fill in around the gap," said García.
By improving communication with the body's cells, García can control the integration and healing response of the body to any implanted device. Currently, most become encapsulated by a collagen sheath, which affects the performance and long-term viability of the device. García aims to use these biomaterials to help integrate devices implanted in the body.
Georgia Institute of Technology Research News
Fibronectin News and Current Fibronectin Events RSSNew step forward in search for solution to infection puzzle
Scientists at the University of York have helped to reveal more about the way bacteria can attach to human tissues.
Study provides clues to prevent spread of ovarian cancer
A drug that blocks production of an enzyme that enables ovarian cancer to gain a foothold in a new site can slow the spread of the disease and prolong survival in mice, according to a study by researchers from the University of Chicago Medical Center, but only if the drug is given early in the disease process.
Researchers discover new way to reverse poor circulation and heal wounds
Researchers have solved a longstanding mystery about how flexing muscles "tell" nearby blood vessels that they need more blood to perform, according to a study published Feb. 15 in the journal Circulation Research.
Developing Kryptonite for Superbug
University of Idaho researchers are crossing academic and geographical bounds to develop more effective defenses against Staphylococcus aureus bacteria and other deadly pathogens.
Potential new way of treating inflammatory diseases identified
Scientists have shown for the first time that platelets, the cells needed for blood clotting, help white blood cells called neutrophils fight inflammation.
Nicotine: The link between cigarette smoking and kidney disease progression?
Cigarette smoke (CS) is the most preventable cause of death and chronic disease in the United States. In addition to being a risk factor for atherosclerosis and cancer, recent epidemiologic studies suggest that cigarette smoke promotes the progression of kidney disease.
Drawing a crowd: How progenitor cells are recruited to tumor blood vessels from the bone marrow
Cells within the bone marrow (progenitor cells) that express a protein called CD34 have been shown to leave the marrow and travel to sites of tissue injury to mediate repair.
Call for research funding to prevent pregnancy complications
State representatives and senators got a call for more research funding to prevent pregnancy complications from a Yale School of Medicine researcher at the 7th annual Women In Government regional conference on September 28.
Don`t smoke while feeding the birds: new research on lung disease
Scientists are developing a method that could prevent lung infections in people who smoke, according to a paper presented today (Wednesday 18 September) at the Society for General Microbiology autumn meeting at Loughborough University. "We've used a human tissue model to show how we can prevent Mycobacterium avium complex (MAC) bacteria from invading cells in the lungs. These bacteria attach themselves to mucus and damaged tissue lining the lungs, and often cause infections in people with existing lung diseases, such as those caused by smoking" says Dr Andrew Middleton, formerly of the Royal Brompton Hospital, London. MAC is closely related to Mycobacterium tuberculosis, which cause
More Fibronectin News Articles
| New Preterm Labor Markers for Early Diagnosis.: An article from: Family Practice News by Doug Brunk This digital document is an article from Family Practice News, published by International Medical News Group on October 15, 1999. The length of the article is 467 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| Immobilization of recombinant retrovirus to fibronectin for gene transfer: Factors that mediate virus binding by Pedro Lei | |
 | Plasma Fibronectin (Hematology Series, Vol 5) by J. Mcdonagh |
| Biosynthesis and Expression of the Human A5b1-Integrin Fibronectin Receptor by B. de Strooper | |
| Preterm labor test viable in real world environment.(Obstetrics) : An article from: OB GYN News by Damian McNamara This digital document is an article from OB GYN News, published by Thomson Gale on March 1, 2006. The length of the article is 465 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Preterm labor... | |
| Heterogeneous Ligand System of Avidin-Biotin and Fibronectin for Enhanced Endothelial Cell Adhesion by Vinayak D Bhat | |
 | Cell Biology of Extracellular Matrix |
| Fibronectin (Biology of Extracellular Matrix) | |
| PLASMA FIBRONECTIN by J. McDonagh | |
| Fibronectin in Health and Disease by Steven E. Carsons |
| © 2008 BrightSurf.com |